Abstract
Low-dose computed tomography screening can be used to diagnose lung cancer at a younger age compared to no screening. Real-world studies observing mortality after lung cancer diagnosis are subject to lead-time bias. This study developed a method using a nationwide cancer registry and stage shift from trial for the adjustment of lead-time bias. 78,897 Taiwanese nationwide lung cancer patients aged 55-82 were matched with 788,820 referents randomly selected from the general population at a ratio of 1:10 by age, sex, calendar year, and comorbidities, to estimate the pathology- and stage-specific life expectancy (LE). Loss-of-LE is the difference between the LE of cancer patients and that of referents. By multiplying LE and loss-of-LE by the pathology and stage shift in the National Lung Screening Trial (NLST), we compared the effectiveness of cancer screening measured by LE gained and loss-of-LE saved. The mean LEs of stage IA and IV adenocarcinoma were 14.5 and 1.9 years, respectively, indicating a LE gain of 12.6 years. However, the mean loss-of-LEs of stage IA and IV adenocarcinoma were 3.7 and 15.1 years, respectively, with a saving of only 11.4 years, implying an adjustment of different distributions of age, sex, and calendar...Continue Reading
References
Oct 1, 1977·Journal of the National Cancer Institute·B HainauS Borgeskov
Aug 9, 2003·Chest·Juan P WisniveskyClaudia Henschke
Apr 15, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Renee ManserDonald A Campbell
Mar 28, 2008·Thorax·J M Reich
Feb 18, 2010·Population Health Management·Sara W GoldbergBruce S Pyenson
Jan 22, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·William D TravisDavid Yankelewitz
Jul 1, 2011·The New England Journal of Medicine·UNKNOWN National Lung Screening Trial Research TeamJoRean D Sicks
Oct 15, 2011·American Journal of Respiratory and Critical Care Medicine·David O WilsonJoel Weissfeld
Mar 7, 2012·Annals of Internal Medicine·Odette WegwarthGerd Gigerenzer
Jun 8, 2013·British Journal of Cancer·M G MarmotM Wilcox
Aug 14, 2013·PloS One·Andrea C VillantiBruce S Pyenson
Sep 7, 2013·Journal of Medical Screening·Paul F PinskyJudith Amorosa
Sep 18, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Amir ShmueliDorith Shaham
Dec 11, 2013·JAMA Internal Medicine·Edward F PatzUNKNOWN NLST Overdiagnosis Manuscript Writing Team
Jan 1, 2014·Annals of Internal Medicine·Virginia A Moyer, UNKNOWN U.S. Preventive Services Task Force
Jan 1, 2014·Annals of Internal Medicine·Harry J de KoningPamela M McMahon
Nov 6, 2014·The New England Journal of Medicine·William C BlackUNKNOWN National Lung Screening Trial Research Team
Feb 11, 2015·Journal of the National Cancer Institute·Pamela M MarcusBarnett S Kramer
Aug 21, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·William D TravisUNKNOWN WHO Panel
Feb 14, 2016·Applied Health Economics and Health Policy·Adam J N RaymakersLarry D Lynd
May 26, 2016·Health Technology Assessment : HTA·John K FieldDavid M Hansell
May 13, 2017·Health Economics·Jing-Shiang HwangJung-Der Wang
Jun 20, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Szu-Chun YangJung-Der Wang
Feb 15, 2018·Thorax·Kevin Ten HaafHarry J de Koning
Nov 13, 2018·Journal of Thoracic Disease·Kai ObayashiHiroyuki Kuwano
Dec 7, 2018·Health Technology Assessment : HTA·Tristan SnowsillChris Hyde
Jul 2, 2019·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·UNKNOWN National Lung Screening Trial Research Team
Jan 30, 2020·The New England Journal of Medicine·Harry J de KoningMatthijs Oudkerk
Mar 10, 2021·JAMA : the Journal of the American Medical Association·UNKNOWN US Preventive Services Task ForceJohn B Wong